A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC)

This study has been terminated.

Study NCT00042302 Information provided by QLT Inc

First Received: July 26, 2002 Last Updated: June 23, 2005 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given